Topiramate and semaglutide work through different mechanisms, and some clinicians may use more than one weight-management medication in selected patients. However, combining medications should be individualized rather than assumed to be appropriate or superior.
Semaglutide is a GLP-1 receptor agonist that reduces appetite and increases satiety. FDA-approved semaglutide products include medications for type 2 diabetes and chronic weight management.
Topiramate is approved for epilepsy and migraine prevention. Its use alone for weight management is off-label, although topiramate is part of the FDA-approved combination phentermine/topiramate extended release.
Combination treatment may be considered when response to one medication is incomplete or when another medication may address a separate clinical issue. Evidence for a specific combination, side-effect burden and patient history all matter.
Potential concerns include nausea, reduced food intake, dehydration, cognitive effects, fatigue and other medication-specific side effects. Pregnancy precautions related to topiramate are particularly important.
Medication combinations should be prescribed only after reviewing other drugs, medical conditions, nutrition, hydration, pregnancy potential and response to prior treatment.
See our semaglutide and weight-loss medication pages.
